Core Insights - Atai Beckley N.V. has been added to the NASDAQ Biotechnology Index, effective December 22, 2025, which reflects the company's growing significance in the biotechnology sector [1][2] Company Overview - Atai Beckley is a clinical-stage biopharmaceutical company focused on developing effective and rapid-acting mental health treatments [4] - The company was formed through the strategic combination of ATAI Life Sciences N.V. and Beckley Psytech Limited in November 2025 [4] Financial and Corporate Developments - In 2025, Atai Beckley raised approximately $300 million to strengthen its balance sheet [2] - The company is advancing multiple clinical programs toward late-stage development, including therapies for treatment-resistant depression and social anxiety disorder [2][4] Pipeline and Therapeutic Focus - Atai Beckley's pipeline includes BPL-003 (mebufotenin benzoate nasal spray), VLS-01 (DMT buccal film), and EMP-01 ((R)-MDMA HCI), all in Phase 2 clinical development [4] - The company is also working on a drug discovery program for non-hallucinogenic 5-HT2AR agonists aimed at treating opioid use disorder and treatment-resistant depression [4] Market Position and Future Outlook - The inclusion in the NASDAQ Biotechnology Index validates Atai Beckley's scientific leadership and positions the company for long-term value creation for patients and shareholders [2] - The NBI serves as a benchmark for investment managers and institutional investors, indicating the company's growing relevance in the investment community [3]